Clinical Trials Logo

Chemotherapy clinical trials

View clinical trials related to Chemotherapy.

Filter by:

NCT ID: NCT03709888 Completed - Clinical trials for Chemotherapy-induced Peripheral Neuropathy

Memantine XR and Pregabalin for Chemotherapy-Induced Peripheral Neuropathy

Start date: July 9, 2016
Phase:
Study type: Observational

Study is designed to assess the efficacy and safety of memantine XR and pregabalin in reducing neuropathic pain in patients with chemotherapy-induced peripheral neuropathy (CIPN) caused by prior treatment with any chemotherapy as measured by the Brief Pain Inventory- Short Form (BPI-SF). It will also determine the influence of these drugs on peripheral neuropathy-related functional status and quality of life (QOL) as measured by the EORTC QLQ-C30.

NCT ID: NCT03687970 Completed - Clinical trials for Chemotherapy-induced Peripheral Neuropathy

A New Method for Identifying Sensory Changes in Painful Chemotherapy-induced Peripheral Neuropathy (CIPN)

Start date: September 17, 2018
Phase: N/A
Study type: Interventional

The investigators propose that using the Diode Laser fiber type Selective Stimulator (DLss) in patients with chemotherapy-induced peripheral neuropathy (CIPN) will allow for the assessment of changes in small-fiber pain thresholds, to identify differences between subjects who received chemotherapy and developed painful CIPN, compared to subjects who received similar chemotherapy but did not develop painful CIPN (control group). Additionally, the investigators would like to investigate whether the response to DLss correlates with pain severity in patients with persistent painful neuropathy. The ultimate goal of this study is to develop a non-invasive, bedside quantitative test that is specific for painful CIPN. If the investigators' initial hypothesis is confirmed, the next step would be to design a prospective longitudinal study and assess changes in DLss early after initiation of chemotherapy, to determine whether this approach can help identify early predictive parameters of painful CIPN.

NCT ID: NCT03674294 Completed - Clinical trials for Gastrointestinal Neoplasms

Aprepitant Triple Therapy for the Prevention of CINV in Nondrinking and Young Women Who Received Moderately Emetogenic Chemotherapy

CINV
Start date: August 4, 2015
Phase: Phase 3
Study type: Interventional

The purpose of this study is to study whether adding Aprepitant to Palonosetron and dexamethasone can further prevent the incidence and severity of nausea and vomiting caused by FOLFIRI or FOLFOX chemotherapy regimen among gastrointestinal malignancy patients with high risk factors of chemotherapy-associated adverse events.

NCT ID: NCT03655587 Completed - Clinical trials for Chemotherapy-induced Peripheral Neuropathy

Impact of an Orthotic Intervention in Children With Peripheral Neuropathy

IOPN
Start date: September 20, 2016
Phase: N/A
Study type: Interventional

This research study will investigate the effect of two orthotic (brace) devices for the ankle and foot on walking and ankle flexibility in children with cancer not involving the brain or spinal cord.

NCT ID: NCT03652727 Completed - Chemotherapy Clinical Trials

FX vs. ECG Guidance for PICC Insertion

Start date: September 4, 2018
Phase: N/A
Study type: Interventional

The aim of this study is to compare two techniques of placing a peripherally inserted central venous catheter (PICC). The first technique, uses ECG based electromagnetic guidance (ECG-EM). The second (reference technique), is guided by X-ray (fluoroscopy).

NCT ID: NCT03649230 Completed - Clinical trials for Chemotherapy-Induced Nausea and Vomiting

Observational Study on the Use of Akynzeo® in Patients Receiving HEC

EVOLVE_CINV
Start date: October 3, 2018
Phase:
Study type: Observational

This Canadian, multi-centre, prospective, observational real-world study is designed to collect patient-reported outcome data on the use of Akynzeo® (netupitant/palonosetron) for the prevention of nausea and vomiting in oncology patients receiving highly emetogenic chemotherapy (HEC).

NCT ID: NCT03582423 Completed - Clinical trials for Chemotherapy Induced Peripheral Neuropathy

Acupuncture for Chemotherapy-induced Peripheral Neuropathy

Start date: October 22, 2018
Phase: N/A
Study type: Interventional

In this study, a 24-week, single blinded, randomized controlled clinical trial will be conducted to examine the efficacy and safety of acupuncture for Chemotherapy Induced Peripheral Neuropathy (CIPN) in colorectal cancer patients in Hong Kong.

NCT ID: NCT03546985 Completed - Clinical trials for Chemotherapy- and/or Radiation-induced Oral Mucositis

A Trial of Episil® Oral Liquid in Cancer Patients Suffering From Chemotherapy- and/or Radiation-induced Oral Mucositis

Start date: December 26, 2017
Phase: N/A
Study type: Interventional

This is a randomized, multi-center, single-use, active-controlled, two-stage open study of episil®. The purpose of this study is to assess the local analgesic effect of episil® in cancer patients suffering from chemotherapy- and/or radiation-induced oral mucositis, which will provide scientific and reliable clinical data in the product registration in China.

NCT ID: NCT03514680 Completed - Cancer Clinical Trials

Clinician Decision Support Algorithm for Chemotherapy-Induced Peripheral Neuropathy

Start date: June 4, 2018
Phase: N/A
Study type: Interventional

This research study is evaluating how well a decision support tool works to improve clinicians' use of recommended chemotherapy-induced peripheral neuropathy (CIPN) assessment and management strategies in participants receiving chemotherapy.

NCT ID: NCT03471078 Completed - Clinical trials for Chemotherapy-induced Thrombocytopenia

Avatrombopag for the Treatment of Chemotherapy-Induced Thrombocytopenia in Adults With Active Non-Hematological Cancers

Start date: October 12, 2018
Phase: Phase 3
Study type: Interventional

Phase 3 randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of avatrombopag in subjects with chemotherapy-induced thrombocytopenia receiving chemotherapy for the treatment of ovarian, lung (small cell and non-small cell) and bladder cancer.